



MEDI-CAPS LIMITED

CIN: L70100MP1983PLC002231

MCL/SE/2025-2026

Date: 24.05.2025

Online filing at: www.listing.bseindia.com

To,
The General Manager
DCS-CRD
BSE Limited
Phiroze Jeejeebhoy Towers, 'A' wing
Dalal Street Fort, Mumbai – 400001(M.H.)

SUBJECT: DISCLOSURE UNDER REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 FOR UPDATE ON U. S. FDA INSPECTION OF WHOLLY OWNED SUBSIDIARY COMPANY, MEDGEL PRIVATE LIMITED.

REFERENCE: MEDI-CAPS LIMITED (BSE SCRIP CODE: 523144, ISIN: INE442D01010)

Dear Sir/Madam,

With reference to the above captioned subject and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in furtherance to intimation dated 24th February, 2025, this is to inform that the United States Food & Drug Administration (USFDA) conducted an inspection at the manufacturing facility of Wholly Owned Subsidiary Company i.e., Medgel Private Limited at Pithampur, Madhya Pradesh, from 17th to 21st February, 2025 and wish to inform you hereby that the company has received a communication from US FDA indicating that the inspection classification of this facility as "Voluntary Action Indicated"(VAI). FDA has concluded that this inspection is "closed" under 21 CFR 20.64 (d) (3).

The above information will also be available on the website of the Company at www.medicaps.com.

You are requested to please take on record the above said information for your reference and further needful.

This is for your information and record.

Thanking You,
Yours Faithfully,

FOR MEDI-CAPS LIMITED

ABHISHEK JAIN
COMPANY SECRETARY &
COMPLIANCE OFFICER
M.N. A36699

REGISTERED OFFICE

201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA INDORE – 452001

PH:- 0731-4028148, FAX:- 0731-4041435

E mail:- investors@medicaps.com, Web site:- www.medicaps.com
